908 Devices Unveils New Glucose and Lactate On-Line Device for Bioprocess Monitoring and Control
January 17 2023 - 7:00AM
Business Wire
MAVEN offers real-time monitoring without
bioreactor volume loss, accelerating process development and
optimizing biologics, cell therapy and gene therapy
manufacturing
908 Devices Inc. (Nasdaq: MASS), a pioneer of handheld and
desktop devices for chemical and biochemical analysis, today
announced the launch of MAVEN, a device for on-line monitoring and
control of glucose and lactate in cell culture and fermentation
processes. MAVEN empowers biopharma companies to make timely
decisions based on highly sensitive, real-time measurements. Taking
measurements as frequently as every two minutes, MAVEN operates
without having to manually draw samples out of the bioreactor due
to its novel aseptic sampling approach. This improves process
understanding, saves operator time and reduces the risk of process
contamination--which in turn accelerates development workflows.
For biopharmaceutical process development scientists who seek to
optimize cell culture and fermentation processes to improve product
yield, quality, efficacy and safety, MAVEN provides highly precise,
on-line monitoring of glucose and lactate without any loss of
bioreactor volume. This enables real-time control of substrate
feeding to maintain optimal nutrient and metabolite concentrations,
even at very low levels. MAVEN is used in concert with the
company’s REBEL device, an at-line cell culture media analyzer that
quantitates over 30 additional key media nutrients in less than 10
minutes.
“While biologics and cell and gene therapies have proven their
ability to make huge advances in human health, costs remain high
due to time-intensive processes,” said Dr. Wolfgang Künnecke, VP of
Bioanalytics R&D, 908 Devices. “We are working diligently to
develop solutions to enhance process understanding and aid in
control. Specifically for glucose and lactate, we are providing
precision measurements that preserve sample integrity and have low
limits of detection. Together MAVEN and REBEL can be used to
improve and optimize cell culture feeding strategies with clarity,
control and ease.”
As an on-line device, MAVEN is a critical part of the
bioprocessing workflow. MAVEN is GMP compliant, takes up a small
footprint in any lab and is incredibly easy to use. In addition,
MAVEN’s ability to precisely monitor concentrations even at very
low levels, 0.01 g/L of glucose and 0.05 g/L of lactate, makes it
particularly beneficial to cell therapy applications where tight
control of cell culture conditions is vital.
“As more advanced therapies enter the pipeline there is an
increasing need for simple, automated on-line devices like MAVEN
for measuring and monitoring process and product attributes,” said
Dr. Kevin J. Knopp, CEO and co-founder, 908 Devices. “MAVEN’s
incorporated aseptic sampling probe serves as an interface for
future on-line analyzers as we broaden our bioanalytics platform
and develop an ecosystem of connected, on-line tools.”
MAVEN is available now worldwide. To learn more, visit
www.908devices.com/products/maven or attend our webinar on January
17 at 11 a.m. ET by registering at
https://908devices.com/now-starts-now. Additionally, check out 908
Devices at industry events, including Advanced Therapies Week
(booth #513) and PepTalk (booth #313).
About 908 Devices
908 Devices is revolutionizing chemical and biochemical analysis
with its simple handheld and desktop devices, addressing
critical-to-life applications. The Company’s devices are used at
the point-of-need to interrogate unknown and invisible materials
and provide quick, actionable answers to directly address some of
the most critical problems in life sciences research,
bioprocessing, pharma/biopharma, forensics and adjacent markets.
The Company is headquartered in the heart of Boston, where it
designs and manufactures innovative products that bring together
the power of mass spectrometry, microfluidic sampling and
separations, software automation, and machine learning.
Forward Looking Statements
This press release includes “forward looking statements” within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements other than statements of historical facts are
forward-looking statements, including, without limitation,
statements regarding the expected uses and capabilities of the
Company’s products. Words such as “may,” “will,” “expect,” “plan,”
“anticipate,” “estimate,” “intend” and similar expressions (as well
as other words or expressions referencing future events, conditions
or circumstances) are intended to identify forward-looking
statements. These forward-looking statements are based on
management’s current expectations and involve known and unknown
risks, uncertainties and assumptions which may cause actual results
to differ materially from any results expressed or implied by any
forward-looking statement, including the risks outlined under “Risk
Factors” and elsewhere in the Company’s filings with the Securities
and Exchange Commission which are available on the SEC's website at
www.sec.gov. Additional information will be made available in the
Company’s annual and quarterly reports and other filings that it
makes from time to time with the SEC. Although the Company believes
that the expectations reflected in its forward-looking statements
are reasonable, it cannot guarantee future results. The Company has
no obligation, and does not undertake any obligation, to update or
revise any forward-looking statement made in this press release to
reflect changes since the date of this press release, except as may
be required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20230117005398/en/
Media Katie Johnston PAN Communications for 908 Devices
908devices@pancomm.com
Investor Carrie Mendivil IR@908devices.com
908 Devices (NASDAQ:MASS)
Historical Stock Chart
From Jul 2024 to Jul 2024
908 Devices (NASDAQ:MASS)
Historical Stock Chart
From Jul 2023 to Jul 2024